Micafungin
- Generic Name
- Micafungin
- Brand Names
- Mycamine
- Drug Type
- Small Molecule
- Chemical Formula
- C56H71N9O23S
- CAS Number
- 235114-32-6
- Unique Ingredient Identifier
- R10H71BSWG
- Background
Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
- Indication
Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been used with some success as primary or salvage therapy, alone or in combination with other antifungals, for the treatment of invasive aspergillosis.
Indicated for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
- Associated Conditions
- Abscesses, Aspergillosis, Candidemia, Candidiasis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Acute disseminated Candidiasis
Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 113
- Registration Number
- NCT01200355
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation
- Conditions
- NeutropeniaHematopoietic Stem Cell TransplantationInvasive Fungal Disease
- Interventions
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2010-09-28
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 145
- Registration Number
- NCT01135589
A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 252
- Registration Number
- NCT01122368
Drug Concentration Analysis of Micafungin in Overweight, Obese, and Extremely Obese Volunteers
- First Posted Date
- 2010-03-19
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 36
- Registration Number
- NCT01090141
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Liver Transplant European Study Into the Prevention of Fungal Infection
- Conditions
- Liver TransplantationMycoses
- Interventions
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 350
- Registration Number
- NCT01058174
Alternate Day Micafungin: A PK Study in Pediatric Patients
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2012-02-16
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 15
- Registration Number
- NCT00842504
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Gary E. Stein, Pharm.D.
- Target Recruit Count
- 21
- Registration Number
- NCT00839540
- Locations
- 🇺🇸
Sparrow Hospital, Lansing, Michigan, United States
An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2013-03-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 13
- Registration Number
- NCT00818584
Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis
- Conditions
- Candidiasis
- Interventions
- First Posted Date
- 2008-12-30
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00815516
- Locations
- 🇷🇴
Emergency County Clinical Hospital, Cluj-Napoca, Romania
🇺🇸WakeMed Health and Hospitals, Raleigh, North Carolina, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Micafungin Lock Therapy
- Conditions
- Catheter-Related Fungal Infections
- Interventions
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2008-12-17
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Target Recruit Count
- 20
- Registration Number
- NCT00809887
- Locations
- 🇺🇸
Children's Medical Center of Dallas/University of Texas Southwestern Medical Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.